2023年7月14日

公司的创新使患者采取精确的血液样本使用一张特别的卡片,然后发送邮政标准进行分析。总经理迈克尔Barbella Editor07.14.23浩了略高于570万美元,扩大和商业化self-sampling技术为远程医疗解决方案和个性化医疗。资金将用于提高生产能力,开发新产品,加大销售和营销努力。投资轮由Sciety和网络Sciety合资企业的合作伙伴。“感谢Sciety的继续支持,我们能够加速增长和扩大生产能力。他们在生命科学专业知识结合行业连接将宝贵的浩在我们继续前进。我们相信,我们的self-sampling技术将成为医疗行业的游戏规则的改变者,为患者提供更大的便利和可访问性,同时保证精确的结果,“浩CEO Christopher Aulin说。浩self-sampling技术使患者采取精确的血液样本使用一张特别的卡片,然后发送分析标准邮政服务不需要制冷或特殊包装。浩正经历着不断增长的需求为其产品在几个市场和最近与几个经销商。浩正努力建立自己self-sampling解决方案的领先供应商的市场领先的临床准确性。 The company's rapid growth has attracted continued support from Sciety and its network Sciety Venture Partners, which have invested in Capitainer for the third time since 2019. "We are excited to invest in Capitainer again and support their vision of revolutionizing blood sample collection. Capitainer's innovative platform has the potential to significantly impact personalised medicine and remote healthcare, which is perfectly in line with Sciety's vision to bring healthcare breakthroughs to people worldwide," Sciety Managing Partner Andreas Lindblom stated. Capitainer AB is a Swedish medtech company founded in 2016 that develops and sells intelligent solutions for self-sampling of blood, plasma, and urine. The company has developed technologies for collecting an exact amount of fluid and then allowing it to dry. The sample card can be sent with regular mail to laboratories without needing refrigerated transports or special packaging. The precision and accuracy in Capitainer’s samples perform on the same level as established pipetting methods. The products can be applied within several market segments, for instance, clinical biomarkers, therapeutic drug monitoring, genomics, drug development, drug abuse and doping testing, and R&D and clinical studies. Trending